Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Wilms Tumor 2 Urothelial Cancer 2 Rhabdoid Tumor 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Glioma 2 Ependymoma 2 Central Nervous System Neoplasms 2 Xanthogranuloma, Juvenile 1 Urinary Bladder Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Prostatic Neoplasms 1 Osteosarcoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Multiple Myeloma 1 Malignant Solid Neoplasm 1 Lymphoma 1 Histiocytic Sarcoma 1 Familial ependymoma 1 Carcinoma, Transitional Cell 1 Breast Neoplasms 1 Advanced Solid Tumor 1

Interventions

ulixertinib 1 tislelizumab 1 talazoparib 1 serabelisib 1 sapanisertib 1 pembrolizumab 1 olaparib 1 mirdametinib 1 lenvatinib 1 erdafitinib 1 crenigacestat 1 atezolizumab 1 Ramucirumab 1 Paclitaxel 1 PM 01183 1 Injections 1 IFL protocol 1 Gemcitabine 1 Bosentan 1 BID protein, human 1 Appointments and Schedules 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Solid Tumor × erdafitinib × Clear all

NCT04083976 2026-05-04

RAGNAR

Janssen Research & Development, LLC

Phase 2 Completed

316 enrolled 15 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡